摘要
骨肉瘤(osteosarcoma,OS)作为最常见的恶性骨肿瘤,在青少年中好发,其5年生存率已经保持了近40年没有改变,维持在60%~70%的水准[1]。其治疗主要还是采取外科手术切除联合多药化疗的标准方案,该方案能够保证未发生转移患者较高的5年生存率,但是对于已经发生转移的患者,即使进行了辅助化疗,其5年生存率依然不足30%[2]。并且,在世界各地进行的一系列临床试验,尝试不同的化疗药物组合和方案.
The 5-year survival rate of osteosarcoma(OS),the most common malignant bone tumor,has remained unchanged at 60%-70%for nearly 40 years.Its treatment mainly relies on surgical resection combined with multi-drug chemotherapy,but it is ineffective for patients with metastasis.In recent years,a series of clinical trials conducted around the world have not effectively improved the 5-year survival rate.However,along with the development of gene sequencing technology and related biomedicines,and the progress of precision medicine,a lot of progress has been made in the research of osteosarcoma driver genes,immune microenvironment,and targeted therapy.In this review,the research progress of osteosarcoma in terms of driver genes,immune microenvironment,and targeted therapy is expounded.
作者
刘净峰
徐鸿锋
刘巍峰
LIU Jing-feng;XU Hong-feng;LIU Wei-feng(Department of Bone Oncology,Beijing Jishuitan Hospital,Beijing,100035,China)
出处
《中国骨与关节杂志》
CAS
2024年第5期390-395,共6页
Chinese Journal of Bone and Joint
基金
国家重点研发计划(2023YFB4706300,2021YFC2400500)
北京市自然科学基金(L212042)
北京市属医院科研培育计划(PX2021015)
北京积水潭医院“学科骨干”计划专项经费资助(XKGG202105)
北京积水潭医院院级科研基金(2023OSR-GCZX202206)。
关键词
骨肉瘤
分子靶向治疗
细胞微环境
驱动基因
综述
Osteosarcoma
Molecular targeted therapy
Cellular microenvironment
Driver genes
Review
